Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke
Not Applicable
- Conditions
- Stroke, Ischemic
- Interventions
- Other: Control groupOther: Intervention group
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06551727
- Locations
- 🇨🇳
Ruijin North Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS
- Conditions
- Ischemic Stroke
- Interventions
- Other: Acute Ischemic Stroke
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 273
- Registration Number
- NCT06549972
- Locations
- 🇨🇳
Neurology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Phase 2
Not yet recruiting
- Conditions
- Follicular Lymphoma
- Interventions
- Drug: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT06549335
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Retrospective Study on Extranodal DLBCL
Completed
- Conditions
- Diffuse Large B Cell LymphomaLymphomaExtranodal Lymphoma
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 5023
- Registration Number
- NCT06549361
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
Recruiting
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Drug: Chimeric Antigen Receptor
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT06541327
- Locations
- 🇨🇳
Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
Not Applicable
Recruiting
- Conditions
- Pancreatic CancerObstructive Jaundice
- Interventions
- Procedure: Traditional strategyProcedure: Modified strategy
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT06541340
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic NeoplasmsNeoplasm MetastasisHepatic Metastasis of Pancreatic Cancer
- Interventions
- Drug: Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, LeucovorinDrug: Tegodor
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06538623
- Locations
- 🇨🇳
Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study on Postoperative Adrenal Function Assessment in Patients With Primary Aldosteronism
Not yet recruiting
- Conditions
- Primary Aldosteronism
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06534268
Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
Recruiting
- Conditions
- SurgeryNon-small Cell Lung Cancer
- Interventions
- Procedure: neoadjuvant immuno-chemotherapy and surgery
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06534489
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, China
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Recruiting
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Other: All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06534463
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath